3-(methylamino)azetidine dihydrochloride

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氮杂环丁烷
• 英文名称: 3-(methylamino)azetidine dihydrochloride
• 英文别名: N-methylazetidin-3-amine hydrochloride；N-methylazetidin-3-amine;hydrochloride
• 化学式: C₄H₁₀N₂*2ClH
• 分子量: 159.059
• InChiKey: IUVWNLGZKLFAGU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.4
• 重原子数：
  7
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  24.1
• 氢给体数：
  3
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-(6-amino-3,5-difluoropyridin-2-yl)-6,7-difluoro-8-methyl-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 、 3-(methylamino)azetidine dihydrochloride 在 lithium hydroxide monohydrate 、 lithium chloride 、 四甲基胍 作用下， 以 二甲基亚砜 为溶剂， 反应 40.0h， 以67%的产率得到1-(6-amino-3,5-difluoropyridin-2-yl)-6-fluoro-8-methyl-7-[3-(methylamino)azetidin-1-yl]-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid
  参考文献：
  名称：

  Discovery of WQ-3810: Design, synthesis, and evaluation of 7-(3-alkylaminoazetidin-1-yl)fluoro-quinolones as orally active antibacterial agents

  摘要：

  Novel 7-(3-allcylaminoazetidin-1-yl)fluoroquinolones were designed, synthesized, and evaluated for their antibacterial activities and oral absorption rates. Against Gram-negative bacteria, 10a-e, which have various alkyl groups containing different numbers of carbon atoms (C0-C3) at the C-7 alkylaminoazetidine position, showed potent and similar antibacterial activities, whereas the activity of 10f (C4, t-Bu) was significantly lower than those of 10a-e. Conversely, the oral absorption rates of 10a-e in rats increased depending on the number of carbon atoms in the alkyl groups; 10d (C3, n-Pr) and 10e (C3, i-Pr) had high oral absorption rates (>90% at 10 mg/kg). These results demonstrated that the introduction of alkyl groups onto C-7 aminoazetidine is useful for the improvement of the oral absorption rates of these drugs while maintaining their antibacterial activities. As a conclusion, from this series of fluoroquinolones, WQ-3810 (10e), having 3-isopropylaminoazetidine as the C-7 substituent, was identified as an orally active antibacterial agent with a potent in vitro activity. (C) 2015 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2015.08.015
• 作为产物：
  描述：

  N-(1-二苯甲基氮杂环丁烷-3-基)-N-甲胺 在 palladium on activated charcoal 盐酸 、 氢气 作用下， 以 甲醇 为溶剂， 生成 3-(methylamino)azetidine dihydrochloride
  参考文献：
  名称：

  抗菌剂，7-杂环胺取代的1-环丙基-6,8-二氟-4-氧喹啉-3-羧酸的定量构效关系。

  摘要：

  各种7-（3-取代的氮杂环丁烷-1-基）-1-环丙基-6,8-二氟-1,4-二氢4-氧代喹啉-3-羧酸的定量构效关系（QSAR），研究了14-25，以阐明3-取代的氮杂环丁烷增强抗菌活性的结构要求。在针对五个代表性革兰氏阴性细菌的相对平均抗菌活性指数GNM与这些分子的计算疏水参数CLOG P之间似乎存在良好的抛物线关系。最有效的导数的CLOG P值预计约为2.3。另一方面，相对于五个代表性的革兰氏阳性细菌，相对于平均抗菌活性指数GPM仍然很高，并且相当恒定，而与氮杂环丁烷部分的结构变化无关。为了证实这些发现，QSAR分析成功地扩展到了喹诺酮羧酸26-34，它带有各种取代的吡咯烷，哌嗪和哌啶衍生物，而不是氮杂环丁烷。结果表明，将任何酰胺取代基引入这些杂环胺部分将导致GNM显着降低，而在远离N-1位置的两个或三个碳原子处引入一些氨基取代基会大大增强GNM。由于氮杂环丁烷喹诺酮类药物在体内的抗菌

  DOI：

  10.1248/cpb.41.126

文献信息

• Pyridonecarboxylic acid derivatives or their salts and antibacterial
  申请人：Wakunaga Pharmaceuticals Co., Ltd.

  公开号：US05998436A1

  公开（公告）日：1999-12-07

  A pyridonecarboxylic acid derivative represented by the following general formula (1): ##STR1## [wherein R.sup.1 represents hydrogen atom or a carboxyl protective group; R.sup.2 represents hydroxyl group, a lower alkoxy group, or a substituted or unsubstituted amino group; R.sup.3 represents hydrogen atom or a halogen atom; R.sup.4 represents hydrogen atom or a halogen atom; R.sup.5 represents a halogen atom or an optionally substituted saturated cyclic amino group; R.sup.6 represents hydrogen atom, a halogen atom, nitro group, or an optionally protected amino group; X, Y and Z may be the same or different and respectively represent nitrogen atom, --CH.dbd. or --CR.sup.7 .dbd. (wherein R.sup.7 represents a lower alkyl group, a halogen atom, or cyano group) (with the proviso that at least one of X, Y and Z represent the nitrogen atom), and W represents nitrogen atom or --CR.sup.8 .dbd. (wherein R.sup.8 represents hydrogen atom, a halogen atom, or a lower alkyl group)] or its salt, as well as an antibacterial agent containing such compound are provided.

  一种吡啶酮羧酸衍生物，由以下通式（1）表示： ##STR1## [其中R1表示氢原子或羧基保护基团；R2表示羟基、低级烷氧基或取代或未取代的氨基；R3表示氢原子或卤素原子；R4表示氢原子或卤素原子；R5表示卤素原子或可选择性取代的饱和环状氨基；R6表示氢原子、卤素原子、硝基或可选择性保护的氨基；X、Y和Z可以相同或不同，分别表示氮原子、--CH＝或--CR7＝（其中R7表示低级烷基、卤素原子或氰基）（条件是X、Y和Z中至少有一个表示氮原子），W表示氮原子或--CR8＝（其中R8表示氢原子、卤素原子或低级烷基）]或其盐，以及含有此类化合物的抗菌剂。
• NOVEL PYRIDONECARBOXYLIC ACID DERIVATIVE OR SALT THEREOF
  申请人：WAKUNAGA PHARMACEUTICAL CO., LTD.

  公开号：US20190276407A1

  公开（公告）日：2019-09-12

  A pyridonecarboxylic acid derivative or a salt thereof is represented by Formula (1), where R 1 is hydrogen, a halogen atom, a lower alkyl group, or an amino group; R 2 is —NH—R 6 , where R 6 is hydrogen, a lower alkyl group, an amino lower alkyl group, or the like; —O—R 7 , where R 7 is hydrogen, a lower alkyl group, or the like; —(CH 2 ) m —R 8 , where R 8 is an amino group or the like, m is 1, 2, 3 or 4; or a cyclic amino group of Formula (2), where Y represents NH or C—R 9a R 9b , where R 9a and R 9b are each independently hydrogen, a lower alkyl group, an amino group, a lower alkyl amino group, or the like; n and p are 1 or 2; R 3 is hydrogen, a halogen atom, a lower alkyl group, or the like; R 4 is hydrogen or a carboxyl group-protecting group; and R 5 is hydrogen or a hydroxyl group-protecting group.

  化合物或其盐可由以下式（1）表示，其中R1是氢、卤素原子、低烷基或氨基；R2是—NH—R6，其中R6是氢、低烷基、氨基低烷基或类似物；—O—R7，其中R7是氢、低烷基或类似物；—(CH2)m—R8，其中R8是氨基或类似物，m为1、2、3或4；或由以下式（2）的环状氨基团表示，其中Y代表NH或C—R9aR9b，其中R9a和R9b各自独立地是氢、低烷基、氨基、低烷基氨基或类似物；n和p为1或2；R3是氢、卤素原子、低烷基或类似物；R4是氢或羧基保护基团；R5是氢或羟基保护基团。
• 1,8 benzonaphthyridine derivatives and antimicrobial compositions
  申请人：Laboratoire Roger Bellon

  公开号：US05556861A1

  公开（公告）日：1996-09-17

  This invention relates to a novel 1,8 benzo[b]naphythyridine derivative of general formula (I), ##STR1## wherein R is H or a hydroxy, amino or alkylamino radical optionally substituted by amino or hydroxy, or R is dialkylamino of which the alkyl portions may form, with the nitrogen atom, a 5- or 6-membered heterocyclic ring which optionally contains a further heteroatom chosen from nitrogen, oxygen or sulphur, or R is C.sub.3-6 cycloalkylamino or an alkanylamino, N-alkyl N-alkanylamino or aminoalkylphenylamino radical; R.sub.1 and R.sub.2, which are the same or different, are in positions 2 and 3 and represent H, alkyl, C.sub.2-4 alkenyl, phenyl, or substituted phenyl, or R.sub.1 and R.sub.2 are in position 2 and represent alkyl; R.sub.3 is H or alkyl, fluoroalkyl, carboxyalkyl, C.sub.3-6 cycloalkyl, fluorophenyl, difluorophenyl, alkyloxy or alkylamino; and R.sub.4 is H or F, wherein the C.sub.1-4 alkanyl and alkyl radicals are linear or branched; stereoisomeric forms thereof or mixtures of these; and salts and hydrated forms thereof. These novel derivatives are useful as antimicrobials.

  这项发明涉及一种新型1,8-苯并[b]萘啉衍生物，其通式为(I)，其中R为H或一个羟基、氨基或烷基氨基基团，该基团可选择通过氨基或羟基进行取代，或R为二烷基氨基，其中烷基部分可以与氮原子形成一个含有氮、氧或硫的5-或6-成员杂环环，或R为C.sub.3-6环烷基氨基或烷基氨基，N-烷基N-烷基烷氨基或氨基烷基苯氨基基团；R.sub.1和R.sub.2在2和3位置，代表H、烷基、C.sub.2-4烯基、苯基或取代苯基，或R.sub.1和R.sub.2在2位置，代表烷基；R.sub.3为H或烷基、氟烷基、羧基烷基、C.sub.3-6环烷基、氟苯基、二氟苯基、烷氧基或烷基氨基；R.sub.4为H或F，其中C.sub.1-4烷基和烷基基团为直链或支链；其立体异构体形式或这些形式的混合物；以及其盐和水合形式。这些新型衍生物可用作抗微生物药物。
• Synthesis and antibacterial activities of novel oxazine and thiazine ring-fused tricyclic quinolonecarboxylic acids: 10-(Alicyclic amino)-9-fluoro-7-oxo-7<i>H</i>-pyrido[1,2,3-<i>de</i>][1,4]benzoxazine-6-carboxylic acids and the corresponding 1-thia congeners
  作者：Tetsuo Okada、Teruji Tsuji、Tadahiko Tsushima、Kiyoshi Ezumi、Tadashi Yoshida、Shinzo Matsuura

  DOI：10.1002/jhet.5570280439

  日期：1991.6

  Several analogs 4 and 5 of Ofloxacin (1) which contain the oxazine and thiazine rings fused with a quinolone carboxylic acid moiety, respectively, were prepared and their in vitro and in vivo antibacterial activities were compared with those of 1 and its previously prepared 3-exo-methylene analogs 2 and 3. Unlike 1, 2, and 3, analogs 4 and 5 possess an antiaromatic oxazine and thiazine moiety and show

  分别制备了氧氟沙星（1）的几种类似物4和5，它们分别包含恶嗪和噻嗪环与喹诺酮羧酸部分稠合，并将其体外和体内抗菌活性与1和先前制备的3进行了比较。外亚甲基类似物2和3。与1、2和3不同，类似物4和5具有抗芳香族恶嗪和噻嗪部分并显示出明显较低的抗菌活性。将它们的C-10氨基取代基从哌嗪改成氮杂环丁烷的方法显着改善了体外抗菌活性，特别是在噻嗪衍生物5的情况下，但在体内却没有。根据分子轨道计算揭示的分子性质，简要讨论了这三种类型的三环喹诺酮羧酸的抗菌活性。分子偶极矩被认为是控制这些化合物与DNA促旋酶结合亲和力的一种可能因素。
• Discovery of WQ-3810: Design, synthesis, and evaluation of 7-(3-alkylaminoazetidin-1-yl)fluoro-quinolones as orally active antibacterial agents
  作者：Kenji Itoh、Yasuhiro Kuramoto、Hirotaka Amano、Daichi Kazamori、Akira Yazaki

  DOI：10.1016/j.ejmech.2015.08.015

  日期：2015.10

  Novel 7-(3-allcylaminoazetidin-1-yl)fluoroquinolones were designed, synthesized, and evaluated for their antibacterial activities and oral absorption rates. Against Gram-negative bacteria, 10a-e, which have various alkyl groups containing different numbers of carbon atoms (C0-C3) at the C-7 alkylaminoazetidine position, showed potent and similar antibacterial activities, whereas the activity of 10f (C4, t-Bu) was significantly lower than those of 10a-e. Conversely, the oral absorption rates of 10a-e in rats increased depending on the number of carbon atoms in the alkyl groups; 10d (C3, n-Pr) and 10e (C3, i-Pr) had high oral absorption rates (>90% at 10 mg/kg). These results demonstrated that the introduction of alkyl groups onto C-7 aminoazetidine is useful for the improvement of the oral absorption rates of these drugs while maintaining their antibacterial activities. As a conclusion, from this series of fluoroquinolones, WQ-3810 (10e), having 3-isopropylaminoazetidine as the C-7 substituent, was identified as an orally active antibacterial agent with a potent in vitro activity. (C) 2015 Elsevier Masson SAS. All rights reserved.